November 20, 2024
SAN DIEGO — Since the adoption of the most recent Model for End-Stage Liver Disease (MELD 3.0) scoring system by the federal Organ Procurement and Transplantation […]
November 20, 2024
TOPLINE: Adding Helicobacter pylori stool antigen (HPSA) testing to a fecal immunochemical test (FIT)–based colon cancer screening program did not reduce gastric cancer incidence or mortality […]
November 19, 2024
PHILADELPHIA — Patients with inflammatory bowel disease (IBD) don’t appear to face an increased risk of major adverse cardiovascular events (MACE) or venous thromboembolism (VTE) when […]
November 19, 2024
TOPLINE: Intermittent calorie restriction (CR) diet is more effective in reducing liver fat content than a standard-of-care diet in patients with metabolic dysfunction–associated steatotic liver disease […]
November 19, 2024
TOPLINE: Aggressive infliximab dosing regimens – intensified induction or accelerated induction – show similar clinical responses and remission rates as the standard infliximab dosing approach in […]
November 19, 2024
TOPLINE: Early initiation of biologic therapy in patients with Crohn’s disease (CD) is associated with higher rates of transmural healing and leads to improved long-term outcomes. […]
November 18, 2024
SAN DIEGO — The prevalence of and number of deaths from alcohol-associated liver disease (ALD) and alcohol use disorder (AUD) are growing among people age 70 […]
November 18, 2024
TOPLINE: Novel first-generation cell-free DNA blood (cf-bDNA) tests for colorectal cancer (CRC) cost more and are less effective than colonoscopy or stool tests, a new analysis […]
November 15, 2024
PHILADELPHIA — New research provides more evidence that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) do not increase the risk for pancreatic cancer. Instead, the large […]